| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06170788 | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab… | Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT06356311 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic… | Gastroesophageal Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06428409 | A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal… | Colorectal Cancer | Recruiting |
| NCT06637423 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer… | Non-Muscle Invasive Bladder Cancer | Recruiting |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in… | Esophageal Squamous Cell Carcinoma | Recruiting |
| NCT06483334 | A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab… | Metastatic Urothelial Carcinoma | Active, Not Recruiting |
| Phase 1 | |||
| NCT06049212 | Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in… | Non-small Cell Lung Cancer | Active, Not Recruiting |